A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the impact of hepatic dysfunction on the
pharmacokinetics and safety of LY2624803 and its major metabolite, LSN2797276.